Screener
Halozyme Therapeutics HALO Compensation and benefits
Compensation and benefits at other companies
Other financials
Where this comes from
Reported directly by Halozyme Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:ShareBasedCompensation.
The source filing: Halozyme Therapeutics’s 10-Q, filed August 6, 2026.
- Filed
- Aug 6, 2026, 4:11 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001159036-26-000104
| Line item | Six Months Ended / June 30, 2026 | Six Months Ended / June 30, 2025 |
|---|---|---|
| Operating activities | ||
| Net income | $379,962 | $283,255 |
| Adjustments to reconcile net income to net cash provided by operating activities: | ||
| Share-based compensation | 34,335 | 22,834 |
| Depreciation and amortization | 8,676 | 5,427 |
| Amortization of intangible assets | 59,024 | 35,524 |
| Amortization of debt discount | 4,499 | 3,698 |
| Accretion of premium on marketable securities, net | (632) | (2,843) |
Item 1. Financial Statements
FAQ
- What is Halozyme Therapeutics's compensation and benefits?
- Halozyme Therapeutics (HALO) reported compensation and benefits of $17.7M in Q2 2026.
- How has Halozyme Therapeutics's compensation and benefits changed year-over-year?
- Halozyme Therapeutics's compensation and benefits increased by 45.5% year-over-year, from $12.16M to $17.7M.
- What does compensation and benefits mean?
- Total employee-related costs including salaries, wages, bonuses, commissions, stock-based compensation, health insurance, retirement contributions, and payroll taxes.
Ask your AI about Halozyme Therapeutics's compensation and benefits.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude